Trial Profile
A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 31 Oct 2019 Status changed from active, no longer recruiting to completed.
- 07 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 29 Jan 2018 Planned End Date changed from 1 Oct 2018 to 1 Sep 2018.